Marlborough medical device manufacturer Boston Scientific Corp. has acquired Obsidio, Inc., a South Carolina-based medical materials developer.
Terms of the deal were not disclosed in Boston Scientific’s Monday announcement.
Obsidio developed Gel Embolic Material, a technology recently cleared by the U.S. Food and Drug Administration to allow physicians to more efficiently reduce blood flow to an abnormality or tumor in the body.
“This acquisition strengthens our interventional oncology and embolization portfolio with a differentiated solution for physicians and their patients suffering from hemorrhages, cancer and other debilitating conditions,” Peter Pattison, president, interventional oncology and embolization, peripheral interventions at Boston Scientific, said in a Monday press release.
